Clinical trials: Sickle Cell Organ Damage
Sickle Cell Disease
Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function
Background: Sickle cell disease (SCD) is a genetic disorder where red blood cells, that carry oxygen, are stiff and become stuck in small blood vessels.
- Trial name
- NCT06145282
- Testing
- Briquilimab, Filgrastim, Abatacept
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hematologic Diseases, Anemia, Sickle Cell
Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia
The purpose of this study is to determine if hydroxyurea therapy is effective in the prevention of chronic end organ damage in pediatric patients with sickle cell anemia.
- Trial name
- NCT00006400
- Testing
- Hydroxyurea
- Where
- 14 sites in United States
- Volunteers
- 193 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)